bioTheranostics Company Profile

News Articles [ 11 Associated News Articles listed on BioPortfolio]

bioTheranostics reports data for molecular cancer classification assay

bioTheranostics Inc. reported data from a study showing that site-specific chemotherapy as directed by the CancerTYPE ID test significantly improved median overall survival (OS) vs. empiric therapy (1...

bioTheranostics Expands Its PRÉCIS Biomarker Profiles and Strengthens Its Industry-Leading Solution for Metastatic Cancer

bioTheranostics, Inc., provider of solutions for metastatic cancer through the development of innovative oncology diagnostic tests, today announced that its PRÉCISSM...

bioTheranostics Adds Chief Medical Officer & Vice President of Medical, Clinical & Regulatory Affairs

bioTheranostics, Inc., a leading provider of molecular diagnostic solutions for metastatic cancer, today announced the appointment of Michael C. Dugan, M.D., as chief medic...

Prospective Study Shows Favorable Overall Survival in Cancer of Unknown Primary Patients With Therapy Directed by bioTheranostics' CancerTYPE ID®

bioTheranostics, developer of innovative oncology diagnostic tests and solution provider for metastatic cancer, today announced study results showing that tumor profiling with its...

bioTheranostics’ Prostate Cancer Index Predicts Risk for Prostate Cancer Recurrence

Study demonstrates clinical validity of new molecular test, which stratifies risk of PSA recurrence and metastasis A new molecular test from bioTheranostics—the Prostate Can...

bioTheranostics Adds Chief Commercial Officer & VP of Corporate Development

bioTheranostics, Inc., a provider of solutions for metastatic cancer through the development of innovative oncology diagnostic tests, today announced that Mary Jo Mullen, c...

bioTheranostics’ CancerTYPE ID® More Accurate than Immunohistochemistry in Diagnosing Metastatic Tumors

bioTheranostics’ CancerTYPE® ID molecular cancer classifier demonstrated superior accuracy compared with immunohistochemistry (IHC) in identifying the primary site...

Prospective Study Shows that Therapy Guided by bioTheranostics’ CancerTYPE ID® Molecular Test Improves Survival in Cancer of Unknown Primary Patients

A four-year prospective study showed that bioTheranostics’ CancerTYPE ID® molecular test successfully predicted the site of origin in patients diagnosed with cancer of unknown...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [ 2 Associated Companies listed on BioPortfolio]

bioTheranostics, Inc.

bioTheranostics discovers, develops, and commercializes a growing array of molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling...

bioTheranostics

Advancing Molecular Diagnostics in Oncology